Table 1 Clinicopathological characteristics of the study population
Characteristic | Entire cohort (n = 313) | Resection only group (n = 104) | Resection with adjuvant therapy group (n = 209) |
|---|---|---|---|
Mean age (range) | 68 (35–101) | 68 (47–101) | 68 (35–100) |
Gender | |||
Male | 230 (73.5%) | 71 (68.3%) | 159 (76.1%) |
Female | 83 (26.5%) | 33 (31.7%) | 50 (23.9%) |
Smoking history | |||
> 10 pack-years | 221 (70.6%) | 78 (75.0%) | 143 (68.4%) |
< 10 pack-years | 92 (29.4%) | 26 (25.0%) | 66 (31.6%) |
Alcohol intake | |||
< 3 U/d | 164 (52.4%) | 52 (50.0%) | 112 (53.6%) |
> 3 U/d | 113 (36.1%) | 40 (38.5%) | 73 (34.9%) |
Missing data | 36 (11.5%) | 12 (11.5%) | 24 (11.5%) |
Primary site | |||
Tonsil | 217 (69.3%) | 68 (65.4%) | 149 (71.3%) |
Base of tongue | 58(18.5%) | 16 (15.4%) | 42 (20.1%) |
Posterior wall / soft palate | 38 (12.2%) | 20 (19.2%) | 18 (8.6%) |
Tumor stage | |||
T1/T2 | 263 (84.0%) | 96 (92.3%) | 167 (79.9%) |
T3/T4 | 50 (16.0%) | 8 (7.7%) | 42 (20.1%) |
Nodal stage | |||
N0 | 92 (29.4%) | 58 (55.8%) | 34 (16.3%) |
N+ | 221 (70.6%) | 46 (44.2%) | 175 (83.7%) |
HR-HPV DNA | |||
Positive | 158 (50.5%) | 42 (40.4%) | 116 (55.5%) |
Negative | 155 (49.5%) | 62 (59.6%) | 93 (44.5%) |
5-year overall survival rate | 76.1% | 69.8% | 79.1% |
5-year disease-specific survival rate | 85.2% | 83.1% | 86.2% |